A multicenter phase II trial of gefitinib 500 mg/day in 193 patients with advanced epidermal growth factor receptor-positive solid tumors who had failed previous chemotherapy: Interim data

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 3162-3162 ◽  
Author(s):  
I. B. Vergote ◽  
Y. Humblet ◽  
E. van Cutsem ◽  
S. van Belle ◽  
J. Kerger ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Solid Tumors ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Growth Factor Receptor ◽  
Multicenter Phase ◽  
Epidermal Growth

scholarly journals Phase II trial of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of anaplastic astrocytoma

2012 ◽  
Vol 2 (1) ◽  
pp. 7-13 ◽  
Author(s):  
Ji H. Kim ◽  
Linna Li ◽  
Tony S. Quang ◽  
Jacqueline G. Emrich ◽  
Theodore E. Yaeger ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Phase Ii ◽  
Anaplastic Astrocytoma ◽  
Phase Ii Trial ◽  
Growth Factor Receptor ◽  
Epidermal Growth

TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 528-528 ◽  
Author(s):  
Rachel A. Freedman ◽  
Rebecca Sue Gelman ◽  
Jeffrey Scott Wefel ◽  
Ian E. Krop ◽  
Michelle E. Melisko ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Brain Metastases ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Growth Factor Receptor ◽  
Her2 Breast Cancer ◽  
Epidermal Growth
Sign in / Sign up

Export Citation Format

Share Document